title: Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma.
abstract: The authors report the case of a 67-year-old woman with metastatic renal cell carcinoma (RCC) without prior nephrectomy, who had received long-term exposure (38 months) to the oral multi-targeted tyrosine kinase inhibitor (TKI), sunitinib. She had a sustained clinical and radiological response to her therapy, but had this therapy discontinued due to the rare development of nephrotic syndrome.
authors.affiliation: Department of Medical Oncology, University Hospital Limerick, Limerick, Ireland.
authors.forename: Keith Ian
authors.initials: KI
authors.lastname: Quintyne
authors.affiliation: Department of Medical Oncology, University Hospital Limerick, Limerick, Ireland.
authors.forename: Triona
authors.initials: T
authors.lastname: Neenan
authors.affiliation: Department of Nephrology, University Hospital Limerick, Limerick, Ireland.
authors.forename: Liam
authors.initials: L
authors.lastname: Casserly
authors.affiliation: Department of Medical Oncology, University Hospital Limerick, Limerick, Ireland.
authors.forename: Rajnish
authors.initials: R
authors.lastname: Gupta
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000556:secondary; D009404:Nephrotic Syndrome / Q000139:chemically induced*; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib